A Clinical Study Of The Second-generation Drug-eluting Stents In The Treatment Of The Coronary Heart Disease

[Objective] To compare the clinical efficacy of the second-generation drug-eluting stents between import Cypher Select Plus and domestic Firebird 2TM; To evaluate the safety and efficacy of second-generation drug-eluting stents in the treatment of patients with coronary heart disease who received percutaneous coronary intervention (PCI).[Methods] From December 2008 to June 2009, all patients accord with research standard in Department of Cardiology, the First Affiliated Hospital, Kunming Medical College, were divided into Cypher2 group and Firebird2 group. PCI were operated conventionally. The patients were followed up after 1 month,4 months and 8 months. Follow-up indicators include:surgical complications, postoperative immediate effect of target vessel, life quality of patients, recurrence of angina pectoris, MACE, stent thrombosis events. The lumen loss of stent, in-stent restenosis and stent thrombosis were reexaminated by imaging.[Result] A total of 84 patients were enrolled in this study, there were 117 stents implanted in 117 target lesions. Between Cypher2 group(38 cases) and Firebird2 group(46 cases),49 Cypher Select Plus stents and 68 Firebird 2TM stents were implanted respectively. The demographic characteristics were similar in the two groups. The angiographic and procedural results were not significantly different between the two groups(P≥0.05). Clinical follow-up was carried out in the two groups. Surgical complications, mortality, recurrence of angina pectoris, MACE and stent thrombosis were almost identical between the two groups at one months, six months and eight months follow up(P≥0.05). There were 24 patients (29.6%) got imaging followed-up at postoperative 239.5±36.1days,7 cases of them received coronary angiography, the other 17 patients received examination of Dual-source 64-slice spiral CT. The late lumen loss of target lesion in Cypher2 group was 0.02mm, the loss index was 0.91%, and in-stent loss index was 0. The late lumen loss of target lesionnd and in-stent in Firebird2 group were 0.04 mm, loss index were 1.54%. There were no significant difference between groups(P≥0.05). No in-stent restenosis and stent thrombosis was found.[Conclusion] Implantation of the Cypher Select Plus stents and Firebird 2TM stents in patients with CHD is effective and safe; The efficacy of near future and medium-term of both stents was similar.